NCT00757757View on ClinicalTrials.gov

A Phase I/II Open-label Study of MCS110 in Patients With Prostate Cancer and Bone Metastases

PHASE1/PHASE2TerminatedINTERVENTIONAL
Enrollment

3

Participants

Timeline

Start Date

September 30, 2008

Primary Completion Date

August 31, 2009

Study Completion Date

August 31, 2009

Conditions
Prostate CancerBone Metastases
Interventions
DRUG

MCS110

Anti-M-CSF antibody

Trial Locations (2)

78229

CTRC, San Antonio

89135

NV Cancer Institute, Las Vegas

Sponsors
All Listed Sponsors
lead

Novartis Pharmaceuticals

INDUSTRY